Cellebrite DI Ltd (NAS:CLBT)
$ 17.96 -0.62 (-3.34%) Market Cap: 3.86 Bil Enterprise Value: 3.63 Bil PE Ratio: 0 PB Ratio: 12.92 GF Score: 53/100

Q2 2024 Cellebrite DI Ltd Earnings Call Transcript

Aug 15, 2024 / 12:30PM GMT
Release Date Price: $14.96 (+7.32%)

Key Points

Positve
  • Cellebrite DI Ltd (CLBT) reported a 26% year-on-year growth in ARR, reaching $346 million by the end of June 2024.
  • The company saw a 25% year-on-year increase in second-quarter revenue, totaling $95.7 million.
  • Cellebrite DI Ltd (CLBT) successfully launched Cellebrite Federal Solutions, enhancing its ability to work with US federal customers.
  • The company is making significant progress with AI integration, which is expected to improve investigative speed, efficiency, and effectiveness.
  • Cellebrite DI Ltd (CLBT) raised its full-year 2024 guidance for both revenue and adjusted EBITDA, reflecting strong performance and future expectations.
Negative
  • Despite strong revenue growth, the ARR guidance raise was more modest, indicating potential challenges in sustaining long-term subscription growth.
  • The company faces ongoing costs related to expanding its sales force and governance, which could impact future profitability.
  • There is a moderate decline in professional services revenue, which could indicate challenges in that segment.
  • The integration of CyTech and the establishment of Cellebrite Federal Solutions come with incremental governance and operational costs.
  • The competitive landscape remains challenging, with other companies emulating Cellebrite DI Ltd (CLBT)'s platform orientation and marketing messaging.
Operator

Welcome to the Cellebrite second quarter 2024 financial results conference call. (Operator Instructions)

I would now like to turn the call over to your first speaker today, Mr. Andrew Kramer. Mr. Kramer, the floor is yours.

Andrew Kramer
Cellebrite DI Ltd - Vice President, Investor Relations

Thank you very much, Todd, and welcome, everybody, to Cellebrite second quarter 2024 financial results call. I'm joined at our offices just outside of Tel Aviv, are Yossi Carmil, Cellebrite's CEO; and Dana Gerner, Cellebrite's CFO. There's a slide presentation that accompanies our prepared remarks. Please advance the slides in the webcast viewer to follow our commentary.

We will call out the slide number we are referring to in our remarks. This call is being recorded and a replay of the recording will be made available on our website shortly after the call, along with a transcript of the event.

Starting with slide number 2, a copy of today's press release and financial statements, including the GAAP-to-non-GAAP reconciliations, the slide

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot